Clinical commissioning policy: Prolonged-released (PR) fampridine as a treatment of adults with multiple sclerosis and associated walking impairment

Document first published:
Page updated:
Topic:
Publication type:

Prolonged-released fampridine is recommended to be available as a routine commissioning treatment option for adults with MS and associated walking impairment (as defined by EDSS score of 4-7) within the criteria set out in this document.

Document

Clinical commissioning policy: Prolonged-released (PR) fampridine as a treatment of adults with multiple sclerosis and associated walking impairment

Clinical commissioning policy: Prolonged-released (PR) fampridine as a treatment of adults with multiple sclerosis and associated walking impairment

  • PDF
  • 267 KB
  • 7 pages

Summary

Published 16 July 2026.